Resolutions of the Annual Shareholders' Meeting of Sartorius AG
At today’s Sartorius AG Annual Shareholders’ Meeting in Goettingen, Germany, shareholders approved the board's proposals by a large majority. The Annual Shareholders' Meeting thus passed the resolution to pay dividends of 0.46 euros per preference share (previous year 0.381 euros) and 0.45 euros per ordinary share (previous year 0.371 euros). The total amount disbursed will rise by 20.5 % year over year from 25.8 million euros to 31.1 million euros. At 23.5 %, the payout ratio is at the level of the previous years (2015: 24.0 %).
During the regular election of shareholder representatives to the Supervisory Board, shareholders re-elected Dr. Lothar Kappich, Prof. Dr. Dres. h.c. Arnold Picot, Prof. Dr. Thomas Scheper and Prof. Dr. Klaus Rüdiger Trützschler. Dr. Daniela Favoccia, Partner of the lawyer’s office Hengeler Mueller, and Ilke Hildegard Panzer, Executive Vice President and Chief Innovation Officer of the BloodCenter of Wisconsin, part of the US-based Health Care-company Versiti Inc., were elected for the first time. The new Supervisory Board will serve for a term of five years.
Furthermore, the Annual Shareholders' Meeting granted discharge to the Supervisory Board and to the Executive Board by a considerable majority. On the whole, more than 500 share owners representing over 96 % of the voting share capital attended this year's Annual Shareholders' Meeting.
1 Adjusted for stock split; rounded values
This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.
Presentation Held by Dr. Joachim Kreuzburg at the Annual Shareholders' Meeting
You will find this presentation and further information on the ASM at: https://www.sartorius.com/sartorius/en/EUR/company/investor-relations/sartorius-ag/shareholders-meeting/2017
Current Image Files
Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG
Sartorius products used in the manufacture of medications
Sartorius products used in biopharma research laboratories
Upcoming Financial Dates
April 24, 2017 Publication of first-quarter figures (January to March 2017)
July 25, 2017 Publication of the first-half figures (January to June 2017)
October 24, 2017 Publication of nine-month figures (January to September 2017)
A Profile of Sartorius
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. Approximately 7,000 people work at the Group's approximately 50 manufacturing and sales sites, serving customers around the globe.
Petra Kirchhoff, Vice President of Corporate Communications
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ASTRAZENECA19.11.2017 00:02 | pressemeddelelse
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases
ASTRAZENECA18.11.2017 19:22 | pressemeddelelse
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer
CHINA-HI-TECH-FAIR18.11.2017 10:13 | pressemeddelelse
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled
NY-MADISON-REALTY17.11.2017 17:22 | pressemeddelelse
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn
NCARDIA17.11.2017 13:33 | pressemeddelelse
Ncardia Announces Completion of €10.5M Investment Round
VOCALINK17.11.2017 10:37 | pressemeddelelse
Double Win for Vocalink at the 2017 Payments Awards
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum